ATNF - 180 Life Sciences Corp.
NASDAQ
->
Healthcare
->
Biotechnology
Palo Alto,
United States
Type: Equity
ATNF price evolution
ATNF
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.98 | $2.66 | $2.01 | $2.65 |
| Short term investments | ||||
| Net receivables | $0.45 | $0.1 | $0.09 | $0.36 |
| Inventory | ||||
| Total current assets | $3.64 | $3.37 | $2.93 | $4.2 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | $1.62 | $1.59 | $1.67 | $1.66 |
| Total noncurrent assets | $1.62 | $1.59 | $10.73 | $10.73 |
| Total investments | ||||
| Total assets | $5.26 | $4.96 | $13.67 | $14.92 |
| Current liabilities | ||||
| Accounts payable | $2.16 | $1.76 | $0.89 | $1.21 |
| Deferred revenue | ||||
| Short long term debt | $1.03 | $0.33 | $0.59 | $0.84 |
| Total current liabilities | $5.06 | $4.81 | $4.27 | $5.12 |
| Long term debt | $0.02 | $0.02 | $0.03 | $0.03 |
| Total noncurrent liabilities | $0.32 | $0.3 | $2.68 | $2.66 |
| Total debt | $1.05 | $0.36 | $0.61 | $0.87 |
| Total liabilities | $5.39 | $5.11 | $6.95 | $7.78 |
| Shareholders' equity | ||||
| Retained earnings | -$127.34 | -$126.12 | -$115.85 | -$112.17 |
| Other shareholder equity | -$2.9 | -$2.85 | -$2.9 | -$2.88 |
| Total shareholder equity | -$0.13 | -$0.15 | $6.72 | $7.14 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.98 | $6.97 | $8.22 | $2.11 |
| Short term investments | ||||
| Net receivables | $0.45 | $0.62 | $0.69 | $0.3 |
| Inventory | ||||
| Total current assets | $3.64 | $8.93 | $11.2 | $4.01 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | $1.62 | $1.66 | $38.94 | $38.95 |
| Total noncurrent assets | $1.62 | $10.72 | $51.51 | $51.52 |
| Total investments | ||||
| Total assets | $5.26 | $19.65 | $62.71 | $55.53 |
| Current liabilities | ||||
| Accounts payable | $2.16 | $1.8 | $0.59 | $8.74 |
| Deferred revenue | ||||
| Short long term debt | $1.03 | $1.31 | $1.91 | $3.67 |
| Total current liabilities | $5.06 | $5.66 | $19.7 | $21.42 |
| Long term debt | $0.02 | $0.03 | $0.05 | $0.11 |
| Total noncurrent liabilities | $0.32 | $2.65 | $3.69 | $3.83 |
| Total debt | $1.05 | $1.34 | $1.96 | $3.78 |
| Total liabilities | $5.39 | $8.31 | $23.39 | $25.25 |
| Shareholders' equity | ||||
| Retained earnings | -$127.34 | -$107.41 | -$68.68 | -$48.36 |
| Other shareholder equity | -$2.9 | -$2.89 | $0.82 | $0.64 |
| Total shareholder equity | -$0.13 | $11.34 | $39.32 | $30.29 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | -$0.04 | $1.1 | $0.92 | $0.79 |
| Selling, general & administrative | $1.49 | $2.43 | $2.76 | $4.01 |
| Total operating expenses | $1.45 | $3.54 | $3.68 | $4.8 |
| Operating income | -$1.45 | -$3.54 | -$3.68 | -$4.8 |
| Income from continuing operations | ||||
| EBIT | -$1.22 | -$12.6 | -$3.67 | -$4.75 |
| Income tax expense | -$0 | -$2.35 | ||
| Interest expense | $0.01 | $0.01 | $0.01 | $0.01 |
| Net income | ||||
| Net income | -$1.23 | -$10.27 | -$3.68 | -$4.76 |
| Income (for common shares) | -$1.23 | -$10.27 | -$3.68 | -$4.76 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.78 | $2.43 | $3.95 | $2.29 |
| Selling, general & administrative | $10.69 | $15.47 | $11.69 | $3.36 |
| Total operating expenses | $13.48 | $17.9 | $15.64 | $5.65 |
| Operating income | -$13.48 | -$17.9 | -$15.64 | -$5.65 |
| Income from continuing operations | ||||
| EBIT | -$22.24 | -$39.64 | -$20.16 | -$9.82 |
| Income tax expense | -$2.35 | -$0.94 | -$0.02 | -$0.02 |
| Interest expense | $0.04 | $0.03 | $0.19 | $1.09 |
| Net income | ||||
| Net income | -$19.94 | -$38.73 | -$20.32 | -$10.88 |
| Income (for common shares) | -$19.94 | -$38.73 | -$20.32 | -$12.01 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$1.23 | -$10.27 | -$3.68 | -$4.76 |
| Operating activities | ||||
| Depreciation | $0.02 | $0.03 | $0.03 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.5 | $0.58 | $0.55 | $0.56 |
| Total cash flows from operations | -$2.16 | -$1.78 | -$3.12 | -$3.87 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.83 | $2.7 | $2.72 | |
| Net borrowings | $0.7 | -$0.26 | -$0.26 | -$0.47 |
| Total cash flows from financing | $1.47 | $2.45 | $2.46 | -$0.47 |
| Effect of exchange rate | $0 | -$0.02 | $0.02 | $0.02 |
| Change in cash and equivalents | -$0.69 | $0.65 | -$0.64 | -$4.32 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$19.94 | -$38.73 | -$20.32 | -$10.88 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.11 | $0.11 | $0.13 |
| Business acquisitions & disposals | $3.01 | |||
| Stock-based compensation | $2.19 | $2.63 | $2.85 | $1.12 |
| Total cash flows from operations | -$10.92 | -$12.13 | -$19.37 | -$3.87 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $11.48 | |||
| Total cash flows from investing | $14.49 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.26 | $11.48 | $24.61 | -$8.93 |
| Net borrowings | -$0.29 | -$0.61 | $0.8 | $0.2 |
| Total cash flows from financing | $5.91 | $10.87 | $25.41 | -$8.73 |
| Effect of exchange rate | $0.02 | -$0 | $0.08 | $0.14 |
| Change in cash and equivalents | -$4.99 | -$1.25 | $6.12 | $2.03 |
News
Fundamentals
| Market cap | $978.54K |
|---|---|
| Enterprise value | $56.80K |
| Shares outstanding | 534.72K |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$22.13M |
| EBIT | -$22.24M |
| Net Income | -$19.94M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.05 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.00 |
| EV/EBIT | -0.00 |
| P/S ratio | N/A |
| P/B ratio | 0.35 |
| Book/Share | 5.19 |
| Cash/Share | 3.70 |
| EPS | -$37.28 |
|---|---|
| ROA | -205.48% |
| ROE | -587.25% |
| Debt/Equity | -42.18 |
|---|---|
| Net debt/EBITDA | -0.15 |
| Current ratio | 0.72 |
| Quick ratio | 0.72 |